share_log

大摩:维持CRISPR Therapeutics(CRSP.US)减持评级,目标价由46.00美元调整至48.00美元。

Damo: The CRISPR Therapeutics (CRSP.US) holdings reduction rating was maintained, and the target price was adjusted from $46.00 to $48.00.

Zhitong Finance ·  Feb 26 23:51

Damo: The CRISPR Therapeutics (CRSP.US) holdings reduction rating was maintained, and the target price was adjusted from $46.00 to $48.00.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment